首    頁特殊之處與一般余甘子比較層疊效應促氧化副作用Q & A專利資料技術資料庫

不是一般的余甘子萃取物:不會有促氧化副作用!!

請認明 ®  註冊商標

 

 

我們的品牌價值是建立在大量科學證據上

 

 STUDIES/JOURNAL ARTICLES

  1. Emblica Cascading Antioxidant: A Novel Natural Skin Care Ingredient
       
    Ratan K. Chaudhuri (
    Dr. Chaudhuri目前是 Capros 生產商 Natreon 研發首席顧問)

文獻摘要

A standardized extract of Phyllanthus emblica (trade named Emblica) was found to have a long-lasting and broad-spectrum antioxidant activity. The product has no pro-oxidation activity induced by iron and/or copper because of its iron and copper chelating ability. Emblica helps protect the skin from the damaging effects of free radicals, non-radicals and transition metal-induced oxidative stress. Emblica is suitable for use in antiaging, sunscreen and general purpose skin care products.

  1. Inhibitory Effect of Phyllanthus emblica Tannins on Melanin Synthesis

Ratan K. Chaudhuri,PhD,Zoia Lascu and Germain Puccetti, PhD

Cosmetics&Toiletries magazine   February 2007 Volume 122. Number 2

  1. Low Molecular Weight Tannins of Phyllanthus emblica- Anti-Aging Effects

Ratan K. Chaudhuri,Cristina Hwang and Germain Puccetti

Cosmetics&Toiletries magazine   January 2004 Volume 119. Number 1

  1. Transition Metal-Induced Oxidation- Implications for Skin Care Products

Ratan K. Chaudhuri and Germain Puccetti

Cosmetics&Toiletries magazine   September 2002 Volume 117. Number 9

  1. Reduction in UV-Induced Skin Pigmentation Using Emblica

  2. Evaluation of Human Skin Fibroblast Cell Viability Under Oxidative Stress in the Presence of Emblica

  3. Measurement of Collagenic and Non-Collagenic Proteins in Human Skin Fibroblast Cells in the Presence of Emblica

  4. Chondroprotective Potential of Phyllanthus emblica in osteoarthritis
    Venil N. Sumantran, Asavari Kulkarni, Rucha Chandwaskar, Abhay Harsulkar,
    Bhushan Patwardhan2, Arvind Chopra3 and Ulhas V. Wagh1

eCAM Advance Access published April 23, 2007

  1. Lipids and Glucose Reduction

Ghosal, S., unpublished work
A human clinical study was performed involving subjects with Type II hyperlipidemia. Test subjects in group A were given a Capros® capsule (250 mg) twice per day. Subjects in group B were given two 250 mg Capros® capsule (500 mg total) twice per day for a period of six weeks.

The study measured total serum cholesterol (TC), serum low density lipoproteincholesterol (LDLC), serum high density lipoproteincholesterol (HDLC) and serum triglyceride (TG). The results clearly showed that Capros® assisted in modest reduction of TC and LDLC with no dose-dependant effects. The study also noted a significant reduction in fasting glucose levels and that the dosage was well tolerated by all subjects. The cholesterol-lowering effects of Emblica extracts have also been demonstrated in numerous animal trials.
 

  1. Rao, T.P. et al. "Amla (Emblica officinalis Gaertn.) extracts reduce oxidative stress in streptozotocin-induced diabetic rats"
    J Med Food 8 (3): 362-8, 2005
    In an animal study, Phyllanthus emblica extracts showed strong free radical scavenging activity. The extract also showed strong inhibition of the production of advanced glycosylated end products. The oral administration of Phyllanthus emblica extracts to diabetic rats slightly improved weight gain and alleviated various oxidative stress indices of the serum of the diabetic rats significantly. The elevated serum levels of 5-hydroxymethylfurfural, a glycosylated protein, an indicator of oxidative stress, were significantly dose-dependently reduced in the diabetic rats that were fed the Phyllanthus emblica extract. Similarly, the serum level of creatinine, another oxidative stress parameter, was also reduced. Furthermore, thiobarbituric acid-reactive substance levels were significantly reduced with Phyllanthus emblica extract, indicating a reduction in lipid peroxidation. In addition, the decreased albumin levels in diabetic rats were significantly improved with Phyllanthus emblica extract. With this, the serum adiponectin levels also improved significantly. These results form the scientific basis supporting the efficacy of Phyllanthus emblica extract for relieving oxidative stress and improving glucose metabolism in diabetes.
     

  1. Prevention of Platelet Aggregation

Ghosal, S., "Method of inhibiting blood platelet aggregation"
US 6,290,996
Reactive Oxygen Species (ROS) can result in lipid peroxidation of membranes. This generates fragments that bind to platelet aggregation factor receptors (PAFs) resulting in platelet aggregation. Capros®, because of its outstanding antioxidant properties, was tested to determine how effective it is in preventing platelet aggregation.

In an in-vitro study, blood platelet aggregation was induced using either ADP or Adrenalin. A series of inhibition samples containing either Capros® or other materials were added to the pre-aggregated blood samples or, in some cases, platelet rich plasma.

The result demonstrated that even at a lower dose than vitamin C or pine bark extract, Capros® by itself, or in combination with vitamin C, inhibited the aggregation of blood platelets significantly more than either vitamin C or pine bark extract samples alone.
 

  1. Gastroprotective

Al-Rehaily, A.J. et al. "Gastroprotective effects of Amla' Emblica officinalis on in-vivo test models in rats"
Phytomedicine, 9(6): 515-522, 2002
An extract of Phyllanthus emblica was examined for its anti-secretory and anti-ulcer activities. In rat models, including pylorus ligation Shay rats, indomethacin, hypothermic restraint stress-induced gastric ulcer and necrotizing agents (80% ethanol, 0.2 M NaOH and 25% NaCl) were employed. Oral administration of Phyllanthus emblica extract at doses 250 mg/kg and 500 mg/kg significantly inhibited the development of gastric lesions in all test models. It also caused significant decrease of the pyloric-ligation induced basal gastric secretion, titratable acidity, and gastric mucosal injury. In addition, Phyllanthus emblica offered protection against ethanol-induced depletion of stomach wall mucus and reduction in nonprotein sulfhydryl concentration. Histopathological analyses are in good agreement with pharmacological and biochemical findings. The results indicate that Phyllanthus emblica extract possesses anti-secretory, anti-ulcer, and cytoprotective properties.

Sairam, K. et al. "Antiulcerogenic effect of methanolic extract of Emblica officinalis: an experimental study"
J Ethnopharmacol, 82 (1): 1-9, 2002
The ulcer protective potential of methanolic extract of Emblica officinalis Gaertn. (EOE) was assessed in different acute gastric ulcer models in rats induced by aspirin, ethanol, cold restraint stress and pyloric ligation and healing effect in chronic gastric ulcers induced by acetic acid in rats. EOE, 10-50 mg/kg administered orally, twice daily for 5 days showed dose-dependent ulcer protective effects in all the above acute ulcer models (36.0-98.3% protection, P < 0.2 to P < 0.001) and significant ulcer healing effect in dose of 20 mg/kg after 5 (control ulcer index: 20.2+/-2.3 mm(2)/rat, % healing 59.6%, P < 0.001) and 10 (control UI: 11.0+/-1.7, % healing 65.5%, P < 0.01) days treatment. Further study on gastric mucosal factors showed that it significantly decreased the offensive factors like acid (acid output-control 118.7+/-12.1 microEq/4 h, EOE% decrease 65.9%, P < 0.01) and pepsin (peptic output-control 738.8 micromol/4 h, EOE% decrease 46.2%, P < 0.001) and increased the defensive factors like mucin secretion (TC:P ratio-control 1.21+/-0.15, EOE% increase 95.0%, P < 0.01), cellular mucus (TC:P ratio-control 1.16+/-0.13, EOE% increase 53.4%, P < 0.05) and life span of mucosal cells (DNA content of gastric juice-control 77.3+/-8.7 microg/m per 100 g body weight, EOE% decrease 42.1%, P < 0.05). EOE showed significant antioxidant effect in stressed animals (control UI 35.8+/-2.5, antioxidant status: LPO 0.58+/-0.03 nmol MDA/mg protein, SOD and CAT 227.8+/-6.3 and 18.4+/-1.2 U/mg protein respectively; EOE% decrease in UI 88.2%, mucosal LPO 69.0%, SOD 53.1% and increase in mucosal CAT 59.8%, P < 0.001 respectively) and did not have any effect on cell proliferation in terms of DNA microg/mg protein or glandular weight. The results showed that EOE had significant ulcer protective and healing effects and this might be due to its effects both on offensive and defensive mucosal factors.
 

  1. Improving Liver Function

  • Tasduq, S.A. et al. "Reversal of fibrogenic events in liver by Emblica officinalis (fruit), an Indian natural drug"
    Biol Pharm Bull, 28(7): 1304-1306, 2005
    An extract of Phyllanthus emblica fruit reduced the severity of hepatic fibrosis induced by carbon tetrachloride CCl4) and thioacetamide (TAA). Improved liver function was observed by measuring the levels of aspartate aminotransaminase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and bilirubin in serum. Hepatic parameters monitored were the levels of glutathione (GSH), lipid peroxidation (LPO) and hydroxyproline and the activities of catalase, glutathione peroxidase (GPx), Na+,K+-ATPase, and cytochrome P450 (CYP 450 2E1) (aniline hydroxylation). The results suggested that the Phyllanthus emblica extract reversed the profibrogenic events. This can be rationalized due to the product's powerful antioxidant properties.

  • Sultana, S. et al. "Emblica officinalis reverses thioacetamide-induced oxidative stress and early promotional events of primary hepatocarcinogenesis" J Pharm Pharmacol, 56(12): 1573-1579, 2004.

    In a study conducted on animals, it was found that Phyllanthus emblica fruit inhibits thioacetamide-induced oxidative stress and hyper-proliferation in rat liver. The administration of a single necrotic dose of thioacetamide(6.6 mM kg(-1)) resulted in a significant (P < 0.001) increase in serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), and gamma-glutamyl transpeptidase (GGT) levels compared to saline-treated control values. Thioacetamide caused hepatic glutathione (GSH) depletion and a concomitant increase in malanodialdehyde (MDA) content. It also resulted in an increase (P < 0.001) in the activity of glutathione-S-transferase (GST), glutathione reductase (GR), glucose 6-phosphate dehydrogenase (G6PD), and a decrease in glutathione peroxidase (GPx) activity (P < 0.001). Hepatic ornithine decarboxylase activity and thymidine incorporation in DNA were increased by thioacetamide administration. Prophylactic treatment with Phyllanthus emblica for seven consecutive days before thioacetamide administration inhibited SGOT, SGPT and GGT release in serum compared with treated control values[ I don't know what is being said]. It also modulated the hepatic GSH content and MDA formation. The plant extract caused a marked reduction in levels of GSH content and simultaneous inhibition of MDA formation. Phyllanthus emblica also caused a reduction in the activity of GST, GR and G6PD. GPx activity was increased after treatment with the plant extract at doses of 100 mg kg (-1) and 200 mg kg (-1). Prophylactic treatment with the plant caused a significant down-regulation of ornithine decarboxylase activity (P < 0.001) and profound inhibition in the rate of DNA synthesis (P < 0.001). In conclusion, the acute effects of thioacetamide in rat liver can be prevented by pre-treatment with Phyllanthus emblica extract.

  • Banu, S.M. et al. "Protective effect of Emblica officinalis ethanolic extract against 7,12-dimethylbenz(a) anthracene (DMBA) induced genotoxicity in Swiss albino mice"
    Hum Exp Toxicol, 23(11): 527-31, 2004.
    In a study conducted on animals, oral administration of Phyllanthus emblica fruit extract in various concentrations (100, 250, 500 mg/kg b.wt) for seven consecutive days prior to a single intraperitoneal injection of rodent carcinogen, 7,12-dimethylbenz(a)anthracene (DMBA) decreased the frequency of bone marrow micronuclei induced in Swiss albino mice. Significant increases in liver antioxidants, such as glutathione (GSH), glutathione peroxidase (GPx), glutathione reductase (GR) and detoxifying enzyme glutathione-S-transferase (GST), were found in the fruit extract treated group. The extract also reduced the hepatic levels of the activating enzymes cytochrome (Cyt) P450 and Cyt b5. These increased in the carcinogen treated group, which emphasizes its protective effect against the carcinogen. There was a dose-dependent effect of the extract against the genotoxin with the maximum effect at 500 mg/kg body weight. The protection afforded by Phyllanthus emblica may be associated with its antioxidant capacity and modulatory effect on hepatic activation and detoxifying enzymes.
     

  1. Radioprotection

  • Singh, I. et al. "Radioprotection of Swiss albino mice by Emblica officinalis"
    Phytother Res, 19(5): 444-6, 2005.
    An extract of Phyllanthus emblica , administered orally at different doses before irradiation was shown to have radioprotective properties against sublethal gamma radiation (9 Gy) in Swiss albino mice. Animals were divided into two groups and irradiated with gamma radiation externally, with or without Phyllanthus emblica extract. The dose of extract found to be most effective against radiation was 100 mg/kg body weight. This dose increased the survival time and reduced the mortality rate of mice significantly. Furthermore, body weight loss in Phyllanthus emblica extract administered irradiated animals was significantly less in comparison with animals who were given radiation only.

  • Hari Kumar, K.B. et al. "Modulation of hematopoietic system and antioxidant enzymes by Emblica officinalis gaertn and its protective role against gamma-radiation induced damages in mice"
    J Radiat Res, (Tokyo), 45(4): 549-555, 2004.
    In another study, the radio protective effect of Phyllanthus emblica was studied in adult Swiss albino mice. Mice were treated with 2.5 g/kg body weight of Phyllanthus emblica for ten consecutive days before irradiation and exposed to a single dose of 700 rads (7Gy) of radiation after the last dose. One group was given Phyllanthus emblica continuously for another fifteen days after irradiation. Changes in the total leukocyte count, bone marrow viability, and hemoglobin were studied after whole body irradiation. Administration of Phyllanthus emblica significantly increased these levels, which were lowered by irradiation. Animals were sacrificed at various time points after irradiation and the activities of the antioxidant enzymes catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPX), and glutathione-S-transferase (GST), and levels of glutathione were assayed in the blood. The damage to the cell membrane after whole body irradiation was studied by measuring the tissue lipid peroxides levels. The results showed that administration of Phyllanthus emblica significantly enhanced the activity of the various antioxidant enzymes (catalase CAT), superoxide dismutase (SOD), glutathione peroxidase (GPX), and glutathione-S-transferase (GST) as well as glutathione system in the blood. Treatment with Phyllanthus emblica also lowered the elevated levels of lipid peroxides in the serum. Phyllanthus emblica extract significantly reduced the bioeffects of radiation.
     

  1. Chemopreventive Actions

Sancheti, G. et al. "Chemopreventive action of Emblica officinalis on skin carcinogenesis in mice"
Asian Pac J Cancer Prev, 6(2): 197-20, 2005.
The inhibition of tumor incidences by implementing Phyllanthus emblica has been evaluated on two-stage process of skin carcinogenesis in Swiss albino mice, induced by a single application of 7, 12-dimethyabenz(a)anthrecene (100 痢 / 100 痞 acetone), and two weeks later, promoted by repeated application of croton oil (1% in acetone/thrice a week) till the end of the experiment (16 weeks). The tumor incidence, tumor yield, tumor Burdon, and cumulative number of papillomas were found to be higher in the control (without Emblica extract treatment) as compared to experimental animals (emblica extract treated). The differences in the values of the results of experimental groups were statistically analyzed and found to be significant in comparison to the control group (p< 0.05). This demonstrates the chemopreventive potential of Phyllanthus emblica fruit extract on DMBA induced skin tumorigenesis in Swiss albino mice.
 

  1. Cough Suppressant

Nosál'ová, G. et al. "Antitussive activity of the fruit extract of Emblica officinalis Gaertn. Euphorbiaceae"
Phytomedicine,10: 583-589, 2003.
The antitussive activity of Phyllanthus emblica was tested in conscious cats by mechanical stimulation of the laryngopharyngeal and tracheobronchial mucous areas of airways. The results showed that at a dose of 50 mg/kg body wt. perorally, the cough suppressive effect of Phyllanthus emblica is not unambiguous. A higher dose (200 mg/kg body weight) of this substance orally was more effective, especially in decreasing the number of cough efforts (NE), frequency of cough (NE/min-1) and the intensity of cough attacks in inspirium (IA+) and expirium (IA-) was more pronounced. These results show that the cough suppressive activity of Phyllanthus emblica is dose-dependent. It was demonstrated that the antitussive activity of Phyllanthus emblica is less effective than shown by the classical narcotic antitussive drug codeine, but more effective than the non-narcotic antitussive agent dropropizine. It is supposed that the antitussive activity of the dry extract of Phyllanthus emblica is due not only to antiphlogistic, antispasmolytic and antioxidant efficacy effects, but also to its effect on mucus secretion in the airways


Agrawala, S.K., Chatterjee, S., and Mishra, S.K. "Immune- Potentiation Activity of a Poly-Herbal Formulation Immu-21 (Research Name)." Phytomedica 2(1&2) (2001), 1-22

Ahmad, I., Mehmood, Z., and Mohammad, F. "Screening of Some Indian Medicinal Plants for Their Antimicrobial Properties." Journal of Ethnopharmacology 62 (1998): 183-193.

Anila, L., and Vijayalakshmi, N.R "Beneficial Effects of Flavonoids From Sesamum Indicum, Emblica officinalis and Momordica charantia." Phytotherapy Research 14 (2000): 592-595.

Aruoma, O. I. et al. . "An Evaluation of the Antioxidant and Potential Pro-Oxidant Properties of Food Additives and of Trolox C, Vitamin E and Probucol." Free Rad. Res. Comms. 10 (1989): 143-157.

Asmawi, M.Z.,et al. "Anti-Inflammatory Activities of Emblica Officinalis Gaertin Leaf Extracts." Journal of Pharmacology 45 (1993): 581-584.


Banu, N. et al. "Role of Amalaki (Emblica officinalis Linn) Rasayana in Experimental Peptic Ulcer." Jour Res Edu Ind Med (1982): 29-34.

Bast, A. et al. "Oxidants and Antioxidants: State of the Art." The American Journal of Medicine 91 (1991).

Bhattacharya, A. et al. "Antioxidant Activity of Active Tannoid Principles of Emblica officinalis (Amla)." Indian Journal of Experimental Biology 37 (1999): 676-680.

Bhattacharya, A. et al. "Effect of Bioactive Tannoid Principles of Emblica officinalis on Iron-Induced Hepatic Toxicity in Rats." Phytomedicine 7 (2000): 173-175.

Bhattacharya, A. Ghosal, S and. Bhattacharya, S.K, "Antioxidant Activity of Tannoid Principles of Emblica officinalis (Amla) in Chronic Stress Induced Changes in Rat Brain." Indian Journal of Experimental Biology 38 (2000): 877-880.

Bhattacharya, S.K., Bhattacharya,D and. Muruganandam,A.V.,. "Effect of Emblica officinalis Tannoids on a Rat Model of Tardive Dyskinesia." Indian Journal of Experimental Biology 38 (2000): 945-947.

Biswas, S, Talukder, G and Sharma,A. "Protection Against Cytotoxic Effects of Arsenic by Dietary Supplementation with Crude Extract of Emblica officinalis Fruit." Phytotherapy Research 13 (1999): 513-516.

Chatterjee, S. "Anti-Peroxide and Radical Scavenging Action of IH/AO-3 a Polyherbal Formulation." Indian J. Indg. Med. 18 (1996): 11-20.

Chaudhuri, R K., and Puccetti, G. Transition Metal-Induced Oxidation: Its Chemistry, Implications and a Strategy in Developing Skin Care Products. Rona/EM Industries, Inc.

Chaudhuri, R. CAPROS - Toxicity Study. 2000.

Chauhan, S. Antioxidant Profile (Lipid Peroxidation) of Capros and Its Derivatives, Vitamin E-Acetate, Ascorbic Acid, Pycnogenol and Natural Tocopherols. Indian Herbs Research & Supply Co. Ltd. 2000.

Chauhan, S. Determination of "Cascade-Type Antioxidant" Property of Capros. Indian Herbs Research & Supply Co. Ltd. 2000.

Chauhan, S. Evidence That Capros Provides Stability to Ascorbic Acid. Indian Herbs Research & Supply Co. Ltd. 2000.

Chauhan, S. Stability Study of Capros. Indian Herbs Research & Supply Co. Ltd. 1999. 1-6.

Chauhan, S. Superiority of Capros Over Other Anti-Oxidants. Indian Herbs Research & Supply Co. Ltd. 2001.

Chawla, Y.K. et al.. "Treatment of Dyspepsia with Amalaki (Emblica officinalis Linn.) - an Ayurvedic Drug." Indian J Med Res 76 (1982): 95-98.

Comparative Antioxidant Activity (DPPH) of Emblica & Natural Antioxidants. Rona, 2001. Cosmetics and Toiletries, 117(2002),43-54

Dahanukar, S.A.,. Kulkarni, R.A. and Rege, N.N. "Pharmacology of Medical Plants and Natural Products." Indian Journal of Pharmacology 32 (2000): s81-s118.

De, J. Accelerated Stability Study of Capros. Indian Herbs Research & Supply Co. Ltd. 2001. 1-8.

Determination of Color Intensity of the Commercial Amla Samples and Capros by Spectrophotometric Method. Indian Herbs Research & Supply Co. Ltd. 2002.

Dharmananda, S. "Emblica Myrobalans: Amla." http://www.itmonline.org/arts/amla.htm. DPPH - TEST - Applied to Pre-Chelated Iron with Antioxidants. Rona/EM Industries .

Effect of Gamma Irradiation on Capros Lot No.547. Indian Herbs Research & Supply Co. Ltd. 2001. 1-11.

Emblica: a Plant-Derived Pro-Oxidation Free Antioxidant for Skin Care. Rona/EM Industries, Inc. 1-26.

Evaluation of Human Skin Fibroblast Cell Viability Under Oxidative Stress in the Presence of Emblica. Rona/EM Industries. 2001.

Evaluation of Phototoxicity Potential by UV-A Irradiation on 20 Human Subjects. AMA Laboratories, Inc. Rona/EM Industries, Inc., 2000.

Evaluation of Phototoxicity Potential by UV-a Irradiation on 20 Human Subjects. Rona/EM Industries, Inc. AMA Laboratories, Inc., 2000.

Ghosal, S . et al. "Active Constituents of Emblica officinalis: Part 1 - the Chemistry and Antioxidative Effects of Two New Hydrolysable Tannins, Emblicanin A and B." Indian Journal of Chemistry 35B (1996): 941-948.

Ghosal, S. "Free Radicals, Oxidative Stress and Antioxidant Defense." Phytomedica 21 (2000): 1-8.

Ghosal, S. "Protective Effect of Capros."

Ghosal, S. Free Radicals, Oxidative Stress and Antioxidant Defense. Drug Research & Development Centre. Calcutta, India.

Ghosal, S. Peak Identification in Capros by HPLC. Indian Herbs Research & Supply Co. Ltd. 2001. 1-12.

Ghosh, A, Sharma,A and Talukder,G. "Comparison of the Protection Afforded by a Crude Extract of Phyllanthus emblica Fruit and an Equivalent Amount of Synthetic Ascorbic Acid Against the Cytotoxic Effects of Cesium Chloride in Mice." Int. J. Pharmacology 31 (1993): 116-120.

Grover, I. S., and Kaur,S. "Effect of Emblica officinalis Gaertn. Indian Gooseberry) Fruit Extract on Sodium Azide and 4-Nitro-O-Phenylenediamine Induced Mutagenesis in Salmonella Typhimurium." Indian Journal of Experimental Biology 27 (1989): 207-209.

Gulati, R.K., Agarwal,S and. Agrawal, S.S. "Hepatoprotective Studies on Phyllanthus emblica Linn. and Quercetin." Indian Journal of Experimental Biology 33 (1995): 261-268.

Hasegawa, N. "Inhibition of Lipogenesis by Pycnogenol." Phytotherapy Research 14 (2000): 472-473.

Haslam, E. "Natural Polyphenols (Vegetable Tannins) as Drugs: Possible Modes of Action." J. Nat. Prod. 59 (1996): 205-215. 1 July 2003 http://pubs.acs.org.

Ihantola-V, Summanen, A.J., Kankaanranta,H Vuorela,H,. Asmawi,A.Z. and Moilanen,A. "Anti-Inflammatory Activity of Extracts From Leaves of Phyllanthus emblica." Planta Medica 63 (1997): 518-524.

Jacob, A, Pandey, M, Kapoor, S and Saroja,R. "Effect of the Indian Gooseberry (Amla) on Serum Cholesterol Levels in Men Aged 35-55 Years." European Journal of Clinical Nutrition 42 (1998): 939-944.

Jose, J K., and Kuttan, R. "Antioxidant Activity of Emblica officinalis." J. Clin. Biochem. Nutr. 19 (1995): 63-70.

Jose, J K., Kuttan, G and Kuttan,R. "Antitumour Activity of Emblica officinalis." Journal of Ethopharmacology 75 (2001): 65-69.

Jose, J, and Kuttan,R. "Hepatoprotective Activity of Emblica officinalis and Chyavanaprash." Journal of Ethnopharmacology 72 (2000): 135-140.

Jose, K., Joy,K.I. and Kuttan, R. "Effect of Emblica officinalis, Phyllanthus amarus and Picrorrhiza kurroa on N-Nitrosodiethylamine Induced Hepatocarcinogenesis." Cancer Letters 136 (1999): 11-16.

Karnick, C.R. "Some Aspects of Crude Indian Drug Plants Used in Ayurvedic System of Medicine for Madhumeya (Diabetes)." Acta Phytotherapeutica 21 (1972).

Krol, W.,. Czuba,Z, Scheller, S, and. Paradowski, Z. "Structure- Activity Relationship in the Ability of Flavonols to Inhibit Chemiluminescence." Journal of Ethnopharmacology 41 (1994): 121-126.

Kumar, A. Accelerated Stability Study of Capros. Indian Herbs Research & Supply Co. Ltd. 2001. 1-15.

Kumar, S, and Muller, K. "Medicinal Plants From Nepal; II. Evaluation as Inhibitors of Lipid Peroxidation in Biological Membranes." Journal of Ethnopharmacology 64 (1999): 135-139.

Mathur, R, Sharma,A, . Dixit, V.P.,and Varma, M. "Hypolipidaemic Effect of Fruit Juice of Emblica officinalis in Cholesterol-Fed Rabbits." Journal of Ethnopharmacology 50 (1996): 61-68.

Measurement of Collagenic and Non-Collagenic Proteins in Human Skin Fibroblast Cells in the Presence of Emblica
. Rona/EM Industries. 2001.

Mishra, M., Pathak,U.N. and Khan, A.B. "Emblica officinalis Gaertn and Serum Cholesterol Level in Experimental Rabbits." Br J Exp Path 62 (1981): 526-528.

Mukhopadhaya, B, Chakrabarti, A., Ghosal,S., and. Bhattacharya, S.K. "Immunomodulatory Properties of Some Indian Medicinal Plants." Emerging Drugs: Volume I - Molecular Aspects of Asian Medicines. Westbury, NY: PJD Publications Ltd., 2001. 445-460.

Naidu, MU.R. et. al. Protective Effect of Gingko Biloba Extract Against Doxorubicin-Induced Cardiotoxicity in Mice. Central Research Laboratory. Hyderabad, India.

Nalini, D., and. Kapoor, R. "Effect of Plant Friuts - Indian Gall Nut, Bedda Nut and Gooseberry - on Hypercholesterolemic Rats." Plant Foods for Human Nutrition 53 (1999): 343-349.

Nandi, P, Talukder, G. and Sharma, A. "Dietary Chemoprevention of Clastogenic Effects of 3,4-Benzo(a)Pyrene by Emblica officinalis Gaertn. Fruit Extract." British Journal of Cancer 76 (1997): 1279-1283.

NartreMax EO: A Pro-Oxidation-Free Cascading-Type Natural Antioxidant. Natreon, Inc. 2001.

Natreon India. "Preparations of Metallo-Capros Complexes." 14 Apr. 2004.

Nemmani, K. et al. "Cell Proliferation and Natural Killer Cell Activity by Polyherbal Formulation, Immu-21 in Mice." Indian Journal of Experimental Biology 40 (2002): 282-287.

Nutritional Support for Emblica. Rona/EM Industries, Inc. 2002.

Ozawa, T, Goto,H., Takazawa,F., and Hanaki, A Formation of the Hydroxyl Radical From Reactions of Copper (II) Complexes with Hydrogen Peroxide. National Institute of Radiological Sciences. 1998. 459-465.

Ozawa, T. DNA Single Strand Breakage by Copper(II) Complexes and Hydrogen Peroxide At Physiological Conditions. 1993.

Packer, L., Rimbach,G., and Virgili,V "Antioxidant Activity and Biologic Properties of a Procyanidin-Rich Extract From Pine (Pinus maritima) Bark, Pycnogenol." Free Radical Biology & Medicine 27 (1999): 704-724.

Paranjpe, P, Patki,P and Joshi, N. "Efficacy of an Indigenous Formulation in Patients with Bleeding Piles: a Preliminary Clinical Study." Fitoterapia 71 (2000): 41-45.

Paranjpe, P, Patki,P., and Joshi, N. "Efficacy of an Indigenous Formulation in Patients with Bleeding Piles: a Preliminary Clinical Study." Fitoterapia 71 (2000): 41-45.

Petrassi, C., Mastromarino,A., and Spartera, C "Pycnogenol¨ in Chronic Venous Insufficiency." Phytomedicine 7 (2000): 383-388.

Prakash, D, Niranjan,A., and Tewari, S.K. "Vitamin C in Emblica Officinalis (Amla) and Its Products." Journal of Medicinal and Aromatic Plant Sciences 22 (2000): 237-241.

Primary Eye Irritation Study in Rabbits. Product Safety Labs. Rona/EM Industries, Inc., 2000. 175-185.

Primary Eye Irritation Study in Rabbits. Rona/EM Industries, Inc. Product Safety Labs, 2000.

Puccetti, G. Comparative Peroxidase H2O2 Inhibitory Activity of Emblica and Other Skin Lightening Ingredients. EMD Chemicals, Inc. 2004.

Puccetti, G. Comparative Tyrosinase Inhibitory Activity of Emblica and Other Skin Lightening Ingredients. EMD Chemicals, Inc. 2004.

Puccetti, G. The Azide Shift Method: Determination of the Efficiency of Chelators on Metals. Rona/EM Industries. 2001.

Puccetti, G. The Deoxyribose Method: Determination of Rate Constants for Reactions of Hydroxyl Radicals. Rona/EM Industries. 2001.

Ramasatri, B.V. "Effect of Storage on the Ascorbic Acid Content of Dehydrated Amla (Emblica officinalis) Powder." The Ind J Nutr Dietet 11 (1974): 134.

Randomized Controlled Clinical Trail of Capros Oral Capsule in Hyperlipidemia. Natreon, Inc. Calcutta, India: Pharma Intel Drug Research & Consultancy Group, 2002.

Reduction in UV-Induced Skin Pigmentation Using Emblica. Rona/EM Industries, Inc. 2002.

Rege, N. N. et al. "Adaptogenic Properties of Six Rasayana Herbs Used in Ayurvedic Medicine." Phytotherapy Research 13 (1999): 275-291.

Reiffen, K - August. Determination of the Characteristic of the Antioxidants in a Two Level Procedure. Merck. 2001.

Reiser, K.M. "Nonenzymatic Glycation of Collagen in Aging and Diabetes." Experimental Biology and medicine 196 (1991):17-29

Report IA: Anti-Hyperglycemic Activity of Capros- Cr Complexes in STZ Treated Rats. Natreon, Inc. India.

Report IB: Capros Chromium Complex and Development of Capros-Based Mettallo-Organic Complexes and Their Chemical and Physiological Implications. Natreon, Inc. India.

Ripper, T. Local Lymph Node Assay in Mice (LLNA). Natreon, Inc. MB Research Laboratories, 2004. 1-23.

Roy, Ajoy Kumar, Haimanti Dhir, Archana Sharma, and Geeta Talukder. "Phyllanthus emblica Fruit Extract and Ascorbic Acid Modify Hepatotoxic and Renotoxic Effects of Metals in Mice." Int. J. Pharmacology 29 (1991): 117-126.

Saliou, C. et al. "Solar Ultraviolet-Induced Erythema in Human Skin and Nuclear Factor-Kappa-B-Dependent Gene Expression in Keratinocytes are Modulated by a French Maritime Pine Bark Extract." Free Radical Biology & Medicine 30 (2001): 154-160.

Scartezzini, P, and Speroni, E. "Review on Some Plants of Indian Traditional Medicine with Antioxidant Activity." Journal of Ethnopharmacology 71 (2000): 23-43.

Sharma, N. et al. "In Vitro Inhibition of Carcinogeninduced Mutagenicity by Cassia occidentalis and Emblica officinalis." Drug And Chemical Toxicology 23 (2000): 477-484.

Sharma, N., Trikha, P., Athar, M and Raisuddin. S. "Inhibitory Effect of Emblica officinalis on the in Vivo Clastogenicity of Benzo [a] Pyrene and Cyclophosphamide in Mice." Human & Experimental Toxicology 19 (2000): 377-384.

Shishoo, C.J., Shah, S.A. , Rathod,I.S., and Patel, S.G.. "Determination of Vitamin C Content of Phyllanthus emblica and Chyavanprash." Indian Journal of Pharmaceutical Sciences (1997): 268-271.

Singh, B.N., and Sharma, P.V. "Effect of Amalaki on Amlapitta." Jour Res Edu Ind Med 5 (1971): 223-230

Srinivasan, M. "Indian Gooseberry (Phyllanthus emblica)." Nature 153 (1944): 684.

Synthesis of L-Ascorbyl-Acyl-Phenolates. Drug Research & Development Centre. Kolkata, India, 2003. 2-28.

Tariq, M., et al. Protective Effect of Fruit Extracts of Emblica officinalis (Gaertn.) & Terminalia belerica (Roxb.) in Experimental Myocardinal Necrosis in Rats. Ms. Aligarh Muslim University, Aligrah. 1977.

Thakur, C.P. "Emblica officinalis Reduces Serum, Aortic and Hepatic Cholesterol in Rabbits." Experientia 41 (1985).

Thakur, C.P., and K. Mandal. "Effect of Emblica officinalis on Cholesterol-Induced Atherosclerosis in Rabbits." Indian J Med Res 79 (1984): 142-146.

Thakur, C.P.,. Thakur, S., Singh, S.,. Sinha,P.K. and. Sinha, S.K "The Ayurvedic Medicines Haritaki, Amla and Bahira Reduce Cholesterol-Induced Atherosclerosis in Rabbits." International Journal of Cardiology 21 (1988): 167-175.

Thorat, S.P., et al. "Emblica Officinalis: a Novel Therapy for Acute Pancreatitis- an Experimental Study." HPB Surgery 9 (1995): 25-30.

Tillotson, A, Singh Khalsa,K.P. and Caldecott, T. "Triphala." Canadian Journal of Herbalism 22 (2001): 16-44.

Velpandian, T., et al. "Preventive Effect of Chyavanprash Against Steroid Induced Cataract in the Developing Chick Embryo." Phytotherapy Research 12 (1998): 320-323.

 

* These statements have not been evaluated by FDA. This product is not intended to diagnose, treat, cure or prevent any disease.© 本網頁提供之產品名、商標、專利、認證、實驗數據、說明等資訊皆為版權所有,未獲授權,請勿複製、擷取、引用、公開。上述資料未經 FDA 證實,不能作為任何功效宣稱、醫療診斷、治療、預防疾病...等用途,請勿公開使用,亦不得引用做為任何商業用途,僅提供做為內部研究評估之用。本網頁所包含的內容與聲明不得視為授權實施或侵害任何本公司或他人所有的任何專利權或其他智慧財產權的建議。終端產品標示、說明、廣告、文宣等,請務必依照當地政府相關規範,使用本網頁內容產生之相關風險或責任應自行承擔。

< Capros及®標誌均為註冊商標,公司名稱、專利號碼、商標等擅用必究。

請認明包裝上有® 註冊商標才是授權真品,來源、品質、含量及安全才有保障。

Contact us at info@capros.com.tw